Lactoferrin-NAC Mucolytic Composition for Long-Term COPD Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Chronic Obstructive Pulmonary Disease (COPD) using N-Acetyl-L-Cysteine alone do not effectively address long-term mucolysis issues and often have side effects, necessitating the development of a safer and more effective mucolytic formulation.

Innovation Solution

A synergistic combination of Lactoferrin and N-Acetyl-L-Cysteine in a specific ratio, optionally with additional active ingredients like Carotenoids, provides enhanced mucolytic effects and reduces oxidative damage in COPD.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If N-Acetyl-L-Cysteine is used alone for COPD treatment, then mucolytic effect is provided, but long-term mucolysis issues persist and side effects occur

Engineering Contradiction:

Improvemucolytic efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines N-Acetyl-L-Cysteine with Lactoferrin to create a composite pharmaceutical formulation. This composite approach leverages the mucolytic properties of NAC while Lactoferrin provides additional benefits including antioxidant activity and anti-inflammatory effects, thereby reducing side effects and improving long-term efficacy in COPD treatment.

Inventive Principle:

Principle #40Composite materials

2Duration of action of stationary object

If N-Acetyl-L-Cysteine is used alone for COPD treatment, then mucolytic effect is provided, but long-term mucolysis issues persist

Engineering Contradiction:

Improvelong-term mucolytic effectVSAvoidmucolysis effectiveness

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent merges N-Acetyl-L-Cysteine with Lactoferrin in a specific formulation where Lactoferrin's stability and antioxidant properties complement NAC's mucolytic action. This combination addresses the limitation of NAC alone by providing sustained mucolytic effect over long-term use through the synergistic interaction between the two components.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12508302B2Pharmaceutical composition providing mucolytic effect

Publication Date: 2025.12.30 FRIMLINE PTE LTD

AI summary

Pharmaceutical compositions or formulations comprising a synergistic combination of N-acetyl-L-cysteine and lactoferrin are disclosed. The pharmaceutical compositions can comprise a combination of N-acetyl-L-cysteine and lactoferrin in a ratio in a range of 11:1 to 14:1. Various compositions or formulations and processes of preparing the same are provided. The pharmaceutical compositions or formulations provide a mucolytic effect, reduce mucus hypersecretion, and/or reduce oxidative damage in patients with chronic obstructive pulmonary disease (COPD).